Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817362 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00817362 is a Phase 2 study that was terminated before completion, run by Infinity Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT00817362, a Phase 2 study, was terminated before completion, sponsored by Infinity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
Interventions
- DRUG Trastuzumab
- DRUG IPI-504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817362
The ClinicalTrials.gov registry entry for NCT00817362 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00817362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817362 about?
NCT00817362 is a clinical study titled "Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer". The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
What is the current status of trial NCT00817362?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2009-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00817362?
The interventions under investigation include: Trastuzumab (DRUG), IPI-504 (DRUG).
Who is sponsoring clinical trial NCT00817362?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.